NASDAQ:IBRX

ImmunityBio News Headlines

$17.38
+0.12 (+0.70 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.15
Now: $17.38
$17.38
50-Day Range N/A
52-Week Range
$3.05
Now: $17.38
$45.42
Volume888,780 shs
Average Volume1.51 million shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

ImmunityBio (NASDAQ IBRX) News Headlines Today

SourceHeadline
ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $16.76ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $16.76
americanbankingnews.com - April 14 at 10:50 AM
ImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher ImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher
americanbankingnews.com - April 13 at 2:34 PM
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine DataImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
finance.yahoo.com - April 9 at 7:25 PM
ImmunityBio is Now Oversold (IBRX)ImmunityBio is Now Oversold (IBRX)
nasdaq.com - April 9 at 7:25 PM
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $18.69ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $18.69
americanbankingnews.com - April 9 at 11:03 AM
Brokers Set Expectations for ImmunityBio, Inc.s Q1 2021 Earnings (NASDAQ:IBRX)Brokers Set Expectations for ImmunityBio, Inc.'s Q1 2021 Earnings (NASDAQ:IBRX)
americanbankingnews.com - April 9 at 8:06 AM
Single Dose Of ImmunityBios Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell ResponsesSingle Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
finance.yahoo.com - April 8 at 6:38 PM
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
finance.yahoo.com - April 8 at 1:38 PM
ImmunityBio (NASDAQ:IBRX) Shares Gap Up  After Analyst UpgradeImmunityBio (NASDAQ:IBRX) Shares Gap Up After Analyst Upgrade
americanbankingnews.com - April 8 at 10:54 AM
ImmunityBio, Inc. (NASDAQ:IBRX) Expected to Post Q1 2022 Earnings of ($0.13) Per ShareImmunityBio, Inc. (NASDAQ:IBRX) Expected to Post Q1 2022 Earnings of ($0.13) Per Share
americanbankingnews.com - April 8 at 7:50 AM
ImmunityBio (NASDAQ:IBRX) Trading 4% Higher  After Analyst UpgradeImmunityBio (NASDAQ:IBRX) Trading 4% Higher After Analyst Upgrade
americanbankingnews.com - April 7 at 12:30 PM
ImmunityBio (NASDAQ:IBRX) Earns Overweight Rating from Piper SandlerImmunityBio (NASDAQ:IBRX) Earns Overweight Rating from Piper Sandler
americanbankingnews.com - April 7 at 8:06 AM
ImmunityBio (NASDAQ:IBRX)  Shares Down 5% ImmunityBio (NASDAQ:IBRX) Shares Down 5%
americanbankingnews.com - April 6 at 1:02 PM
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $23.74ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $23.74
americanbankingnews.com - April 1 at 10:54 AM
ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of DirectorsImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors
finance.yahoo.com - April 1 at 9:45 AM
ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.9%ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.9%
americanbankingnews.com - March 30 at 12:42 PM
ImmunityBio, Inc. (IBRX)ImmunityBio, Inc. (IBRX)
in.finance.yahoo.com - March 29 at 2:53 PM
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate CancerImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
finance.yahoo.com - March 29 at 2:53 PM
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $30.89ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $30.89
americanbankingnews.com - March 26 at 11:40 AM
ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual FormulationsImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations
finance.yahoo.com - March 23 at 10:54 AM
ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant TumorsImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors
finance.yahoo.com - March 23 at 10:54 AM
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.